Telix Acquires Optimal Tracers – QNT Press Release


MELBOURNEAustralia and INDIANAPOLIS, Ind., Nov. 13, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials.

The acquisition of Optimal Tracers will bolster Telix’s in-house radiochemistry development capability, by adding a highly skilled team to Telix and establishing a US-based laboratory and production footprint for clinical trial doses. The acquisition includes a facility with a radiation and pharmaceutical manufacturing licence sufficient to cover the Company’s key diagnostic and therapeutic isotope requirements for pre-clinical and clinical research purposes. The acquisition of Optimal Tracers aligns with Telix’s strategy to build a degree of vertical integration, improve in-house research and radiopharmaceutical development capability and further develop novel tracers in its pipeline. Optimal Tracers will also remain available as a strategic collaborative resource to partner organisations and pharma collaborators that need access to specialist radiochemistry domain knowledge.

Located in a translational research hub at the University of California, Davis (UCD), Optimal Tracers is a specialised business that provides development services and clinical trial doses to pharmaceutical and biotech companies, as well as academic research institutions. Optimal Tracers is advantageously located to service leading clinical sites along the West Coast of the United Stateswith capability to deliver certain research products across the entire country.

Jonathan BarlowSVP Global Business Development & Alliance Management said, “Optimal Tracers is an established business, with a highly regarded team and impressive client roster. They have built a strong reputation based on their deep …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center